Aducanumab

Biogen is abandoning its lackluster Alzheimer’s disease drug, Aduhelm. The Massachusetts-based company announced Wednesday that it is pulling the medication from the market following poor sales and controversy over its approval by the Food and Drug Administration in 2021. The company says it is only doing so to “reprioritize” its resources toward its other, less contentious Alzheimer’s treatments, such as Leqembi.Lisa Frankenstein's Crew on Casting the Right Stars Adulhelm was developed by Biogen in conjunction with the…

On Thursday, the Food and Drug Administration made a decision that’s likely to have a major impact on the landscape of Alzheimer’s disease research. The agency issued a full-throated traditional approval of the drug Leqembi, developed by the companies Eisai and Biogen. The drug is the first of its class to receive such approval and is intended to slow down the progression of the neurodegenerative disease.Will We See More of Uhura's Relationship with Spock? | io9 InterviewLeqembi is one of several antibody-based drugs that…

Image: Shutterstock (Shutterstock)An experimental drug for Alzheimer’s disease appears to have shown successful results in a major large-scale clinical trial. The drug’s makers announced Tuesday that their treatment slowed down people’s rate of cognitive decline in a Phase III trial. The findings will likely pave the way for the drug’s approval in the U.S. and elsewhere, but there are still important questions left unanswered about its practical benefits to Alzheimer’s patients.The treatment is known as lecanemab, and…